Perspectives
Engaging Medicare members improves adherence, can lead to higher Star ratings
November 15, 2015When members don’t take their medicine as prescribed, it can lead to increased hospitalizations and poor health outcomes. For Medicare plan sponsors, nonadherence drives up unnecessary health care costs. And the financial impact doesn’t end there.
Adherence measures account for 28 percent of a Prescription Drug Plan’s (PDP) Star ratings. Encouraging adherence and achieving a high Star rating are top priorities, and for good reason. In 2015, plans with ratings of less than four stars will lose out on an estimated $3.47 billion in bonus payments.1
What we studied
The Centers for Medicare and Medicaid Services requires PDP sponsors to provide Medication Therapy Management (MTM) programs to help optimize health outcomes. To learn how MTM programs impact adherence — and eventually Star ratings — our team of researchers analyzed pharmacy claims data for 1.2 million Medicare members. We compared adherence between qualified members who engaged in MTM* vs. those who did not within the three drug adherence Star ratings categories: diabetes, statins and renin angiotensin system (RAS) antagonists).
What we learned
When analyzing the data, Prime found significant correlation with engagement in an MTM program and adherence. The proportion of adherent members who participated in MTM were:
- 40 percent higher for oral diabetes medicine
- 20 percent higher for statins
- 20 percent higher for RAS antagonists
Why we did this study
Understanding how MTM impacts adherence is an important part of PDP sponsors’ Star ratings strategy. Our findings validate the importance of promoting MTM programs and making it easy for members to participate. Focusing on MTM engagement not only sets the stage for financial success — it helps ensure that members are getting the medicine they need to feel better and live well.
Related news
Perspectives
July 25, 2024
Quarterly Drug Pipeline: July 2024
Clinical insights and competitive intelligence on anticipated drugs in development
Perspectives
July 22, 2024
Oncology Insights: 2024 ASCO Annual Meeting key findings
Findings from this year’s American Society of Clinical Oncology (ASCO) Annual Meeting will likely lead to clinical practice changes and U.S. Food and Drug Administration (FDA) drug approvals or expansions
Perspectives
July 16, 2024
LISTEN NOW: Beyond the business – Stories of corporate kindness | Pharmacy Friends Podcast
In this episode, we talk about how our employees' help goes beyond our work in health care, aiding in philanthropic efforts